Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esteban Braggio

Showing results (41-50 of 144) with videos related to

Pageof 15
Sort By:
Blood|December 29, 2016
Multiple myeloma cells' capacity to decompose H<sub>2</sub>O<sub>2</sub> determines lenalidomide sensitivitySinto Sebastian, Yuan X Zhu, Esteban Braggio, et al.
Blood|November 15, 2014
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2Yuan Xiao Zhu, Hongwei Yin, Laura A Bruins, et al.
Blood Cancer Journal|February 12, 2019
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Yuan Xiao Zhu, Chang-Xin Shi, Laura A Bruins, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapyNeil E Kay, Jeanette E Eckel-Passow, Esteban Braggio, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 26, 2018
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case reportYanira Ruiz-Heredia, Beatriz Sanchez-Vega, Santiago Barrio, et al.
Blood Cancer Discovery|September 21, 2020
Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progressionMarta Chesi, Caleb K Stein, Victoria M Garbitt, et al.
Leukemia|August 20, 2025
Progressive T cell defects correlate with disease outcome in high-count monoclonal B-cell lymphocytosisSameer A Parikh, Nikolaos Ioannou, Alan G Ramsay, et al.
Ejhaem|September 2, 2022
Transcriptional profiles define drug refractory disease in myelomaYuan Xiao Zhu, Laura A Bruins, Xianfeng Chen, et al.
Blood|August 24, 2011
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 4, 2012
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesEsteban Braggio, Ahmet Dogan, Jonathan J Keats, et al.
Pageof 15

Showing results (41-50 of 144) with videos related to

Sort By:
Pageof 15
Blood|December 29, 2016
Multiple myeloma cells' capacity to decompose H<sub>2</sub>O<sub>2</sub> determines lenalidomide sensitivitySinto Sebastian, Yuan X Zhu, Esteban Braggio, et al.
Blood|November 15, 2014
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2Yuan Xiao Zhu, Hongwei Yin, Laura A Bruins, et al.
Blood Cancer Journal|February 12, 2019
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4Yuan Xiao Zhu, Chang-Xin Shi, Laura A Bruins, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapyNeil E Kay, Jeanette E Eckel-Passow, Esteban Braggio, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 26, 2018
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case reportYanira Ruiz-Heredia, Beatriz Sanchez-Vega, Santiago Barrio, et al.
Blood Cancer Discovery|September 21, 2020
Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progressionMarta Chesi, Caleb K Stein, Victoria M Garbitt, et al.
Leukemia|August 20, 2025
Progressive T cell defects correlate with disease outcome in high-count monoclonal B-cell lymphocytosisSameer A Parikh, Nikolaos Ioannou, Alan G Ramsay, et al.
Ejhaem|September 2, 2022
Transcriptional profiles define drug refractory disease in myelomaYuan Xiao Zhu, Laura A Bruins, Xianfeng Chen, et al.
Blood|August 24, 2011
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 4, 2012
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesEsteban Braggio, Ahmet Dogan, Jonathan J Keats, et al.
Pageof 15